U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

Patients treated with IMBRUVICA plus obinutuzumab experienced a 77 percent reduction in risk of progression or death compared to chlorambucil plus obinutuzumab Approval broadens the label in frontline CLL and represents the tenth FDA approval for IMBRUV... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news